Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy

被引:32
|
作者
Sisti, Eleonora [1 ,2 ]
Coco, Barbara [3 ]
Menconi, Francesca [1 ,2 ]
Leo, Marenza [1 ,2 ]
Rocchi, Roberto [1 ,2 ]
Latrofa, Francesco [1 ,2 ]
Profilo, Maria Antonietta [1 ,2 ]
Mazzi, Barbara [1 ,2 ]
Vitti, Paolo [1 ,2 ]
Marcocci, Claudio [1 ,2 ]
Brunetto, Maurizia [3 ]
Marino, Michele [1 ,2 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, Endocrinol Units, I-56124 Pisa, Italy
[2] Univ Hosp Pisa, I-56124 Pisa, Italy
[3] Univ Hosp Pisa, Hepatol Unit, Pisa, Italy
关键词
AUTOIMMUNE HEPATITIS; METHYLPREDNISOLONE; OPHTHALMOPATHY; MANAGEMENT; PATIENT; DISEASE;
D O I
10.1089/thy.2015.0061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: High-dose intravenous glucocorticoid (ivGC) pulse therapy, which is commonly used for Graves' orbitopathy (GO), has been associated with acute liver damage (ALD), resulting in a fatal outcome in a few cases. No certain risk factors for ALD have been established. Consequently, a large retrospective cohort study was performed. Methods: The relationship between ALD and several potential risk factors was assessed in 1076 consecutive patients with GO given ivGC. ALD was defined as an increase of alanine aminotransferase 300IU/L. Results: Fourteen cases of ALD were recorded, resulting in a morbidity of 1.3%. Thirteen patients recovered and one died, resulting in a mortality of 0.09%. There was a significant, positive correlation of ALD with age and methylprednisolone acetate (MPA) cumulative dose, and ALD was more common (relative risk [RR]=2.8; p=0.05) in patients aged 53 years (9/420; 2.14%) than in those aged <53 years (5/656; 0.76%). In patients aged 53 years, there was a significant positive correlation of ALD with MPA cumulative dose, and with MPA dose per infusion. Thus, the frequency of ALD in this age group was greater (RR=3.48; p=0.04) in patients with a MPA dose per infusion 0.7g (5/111, 4.5% vs. 4/308, 1.29%). Regardless of age, no cases of ALD were observed for MPA doses per infusion <0.57g. Conclusions: Age and MPA dose are significant risk factors for ALD, with the following practical implications. First, the total MPA cumulative dose should not exceed 8.5g (the average dose in patients without ALD). Second, in patients aged 53 years, selection and observation should be quite strict. However, being aged 53 years should not be seen as an absolute contraindication to ivGC, especially in patients with severe GO, considering that the risk of ALD, although statistically significant, was relatively low. Third, the MPA dose should not exceed 0.57g per infusion, a measure to be applied regardless of age.
引用
收藏
页码:846 / 850
页数:5
相关论文
共 50 条
  • [41] High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy
    Kauppinen-Mäkelin, R
    Karma, A
    Leinonen, E
    Löyttyniemi, E
    Salonen, O
    Sane, T
    Setälä, K
    Viikari, J
    Heufelder, A
    Välimäki, M
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 2002, 80 (03): : 316 - 321
  • [42] Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease
    Weissel, M
    Hauff, W
    THYROID, 2000, 10 (06) : 521 - 521
  • [43] Age, Initial Dose and Dose Increase are Independent Risk Factors for Symptomatic Vertebral Fractures in Glucocorticoid-Treated Male Patients
    Sugiyama, Takao
    Suzuki, Sawako
    Yoshida, Tomohiko
    Mayama, Takafumi
    Hashimoto, Naoko
    Suyama, Keiko
    Tanaka, Tomoaki
    Sueishi, Makoto
    Tatsuno, Ichiro
    INTERNAL MEDICINE, 2011, 50 (08) : 817 - 824
  • [44] Evaluation of macular blood flow after intermittent intravenous infusion of high-dose corticosteroids (pulse therapy) in patients with thyroid-associated orbitopathy (TAO) using angio-OCT
    Chiara Del Noce
    Matilde Roda
    Lorenzo Ferro Desideri
    Carlo E. Traverso
    Aldo Vagge
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 571 - 576
  • [45] Evaluation of macular blood flow after intermittent intravenous infusion of high-dose corticosteroids (pulse therapy) in patients with thyroid-associated orbitopathy (TAO) using angio-OCT
    Yuksel, Nilay
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (12) : 4025 - 4025
  • [46] Evaluation of macular blood flow after intermittent intravenous infusion of high-dose corticosteroids (pulse therapy) in patients with thyroid-associated orbitopathy (TAO) using angio-OCT
    Del Noce, Chiara
    Roda, Matilde
    Desideri, Lorenzo Ferro
    Traverso, Carlo E.
    Vagge, Aldo
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (02) : 571 - 576
  • [47] Evaluation of macular blood flow after intermittent intravenous infusion of high-dose corticosteroids (pulse therapy) in patients with thyroid-associated orbitopathy (TAO) using angio-OCT
    Nilay Yuksel
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 4025 - 4025
  • [48] The prevalence and risk factors of hepatitis B flares in chronic hepatitis B patients receiving glucocorticoid pulse therapy
    Ying-Cheng Lin
    Shou-Wu Lee
    Hong-Zen Yeh
    Chi-Sen Chang
    Sheng-Shun Yang
    International Journal of Clinical Pharmacy, 2018, 40 : 169 - 174
  • [49] Graves’ hyperthyroidism and ophthalmopathy associated with pemphigus vulgaris: Onset of thyroid autoimmune disease during chronic low-dose glucocorticoid therapy
    L. Bartalena
    F. Bogazzi
    L. Chiovato
    M. L. Tanda
    E. Martino
    Journal of Endocrinological Investigation, 1997, 20 : 155 - 157
  • [50] The prevalence and risk factors of hepatitis B flares in chronic hepatitis B patients receiving glucocorticoid pulse therapy
    Lin, Ying-Cheng
    Lee, Shou-Wu
    Yeh, Hong-Zen
    Chang, Chi-Sen
    Yang, Sheng-Shun
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 169 - 174